This trial was designed to evaluate the safety of NTx-265 in patients suffering acute ischemic stroke and to conduct a preliminary assessment of functional recovery in this patient population.
Results from the BETAS trial showed no serious adverse events related to NTx-265 in the 13 patients enrolled. Of these, eight patients completed the 90 day assessment term and each of them showed a clinically relevant improvement in their National Institutes of Health Stroke Scale (NIHSS) score of four points or greater. Patients entered the trial with NIHSS scores ranging from 6-19 (moderate to severe).